Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.
Chris Mazzolini
Advertisement
Articles by Chris Mazzolini
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Patient Care Online
1
2025-2026 Flu Season: Reduced Vaccine Match May Lead to Increased Transmission and Severity, Experts Warn
2
Atopic Dermatitis Management Beyond Skin Symptoms in Primary Care
3
Geriatric NP Carolyn Clevenger Discusses Agitation in Alzheimer Disease: Overlooked, Misunderstood, and Progressive
4
Novo Nordisk Seeks FDA Approval for Higher-Dose Semaglutide 7.2 mg for Chronic Weight Management
5
